Specialized CRO Models Will Expand Drug Discovery Amid Uncertainty

Key Takeaways

• Expansion of proprietary peptide pipeline and major partnerships diversify revenue streams and enhance earnings resilience beyond core CRO services.
  
• Investments in advanced preclinical platforms and global reach position Gubra to capture a larger, higher-margin market as outsourcing in biotech grows.
  
• Heavy reliance on volatile markets, concentrated revenue sources, and traditional services exposes Gubra to profitability risks amid funding constraints, geographic limits, and evolving alternatives.

Catalysts

A biotech company, focuses on the pre-clinical contract research and peptide-based drug discovery within metabolic and fibrotic diseases in Europe, North America, and internationally.

• The rising global prevalence of obesity, diabetes, and related metabolic diseases is expanding the pipeline of drug development projects, supporting sustained long-term demand for Gubra's specialized CRO and Discovery & Partnerships services-positioning the company for resilient revenue growth despite near-term CRO market softness.
  
• The ongoing industry shift toward outsourcing R&D to specialized, data-driven CROs is likely to boost Gubra's addressable market over time; Gubra's investments in advanced preclinical models and proprietary platforms position it to capture a greater share of higher-margin, complex research projects, which should enhance both revenue and future net margins.
  
• Expansion and clinical advancement of the proprietary peptide pipeline (Amylin/GUBamy, UCN2) creates meaningful optionality for future milestone payments, licensing income, and potential royalties; these flows can meaningfully supplement and diversify earnings away from cyclical CRO service revenue.
  
• Recent major partnership and upfront payment from AbbVie (Amylin/GUBamy) demonstrate validation of Gubra's drug discovery capabilities and business model, while positive early human trial data could catalyze additional partnerships, driving lumpier but higher long-term earnings and cash flow potential.
  
• Strategic moves to broaden geographic reach into the U.S. and Asia-Pacific-and new service offerings (e.g., women's health)-should diversify the client and revenue base, reduce exposure to single-market downturns, and incrementally enhance topline growth and operating leverage over the long run.

Gubra Future Earnings and Revenue Growth

Assumptions

How have these above catalysts been quantified?

• Analysts are assuming Gubra's revenue will decrease by 16.9% annually over the next 3 years.
• Analysts assume that profit margins will shrink from 64.1% today to 48.6% in 3 years time.
• Analysts expect earnings to reach DKK 734.8 million (and earnings per share of DKK 45.08) by about June 2029, down from DKK 1.7 billion today. However, there is a considerable amount of disagreement amongst the analysts with the most bullish expecting DKK835.2 million in earnings, and the most bearish expecting DKK314.5 million.
• In order for the above numbers to justify the price target of the analysts, the company would need to trade at a PE ratio of 12.0x on those 2029 earnings, up from 3.3x today. This future PE is lower than the current PE for the DK Life Sciences industry at 19.8x.
• Analysts expect the number of shares outstanding to decline by 0.07% per year for the next 3 years.
• To value all of this in today's terms, we will use a discount rate of 6.12%, as per the Simply Wall St company report.

Risks

• Macro-driven funding constraints in the U.S. market, particularly affecting small biotechs and academia, have already led to a 2% decline in CRO revenue in the first half of 2025 and a downward revision of full-year guidance; prolonged weakness in biotech capital availability presents an ongoing risk to revenue growth and overall earnings, given Gubra's material exposure to this segment.
  
• Despite a strong proprietary pipeline and major partnership deals, Discovery & Partnerships revenue remains "lumpy," highly dependent on successful milestone achievements, upfront payments, and partners' decisions (e.g., AbbVie controls GUBamy development); this dependence increases volatility in revenue and earnings, potentially impacting the stability needed for consistent share price appreciation.
  
• Expansion into new service areas (like women's health) requires upfront investment in personnel and capabilities, which has contributed to lower EBIT margin guidance for the CRO segment (revised to around 20% from a previous 25–31%); should these investments not yield sufficient incremental revenue, sustained margin compression may weigh on profitability and net incomes.
  
• The company's revenue base is still geographically concentrated, with U.S. and European markets dominating; limited penetration into Asia and reliance on the U.S. amplify exposure to regional economic or regulatory downturns, thereby increasing the risk of revenue stagnation and elevated earnings volatility.
  
• Growth in alternative preclinical technologies-such as organ-on-a-chip, computational drug discovery, and AI-based models-could erode demand for Gubra's core animal model services amidst increasing regulatory and ESG scrutiny of animal research, posing a long-term threat to both revenue and margin sustainability if Gubra cannot adapt or diversify in response.

Valuation

How have all the factors above been brought together to estimate a fair value?

• The analysts have a consensus price target of DKK451.5 for Gubra based on their expectations of its future earnings growth, profit margins and other risk factors.
• However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of DKK500.0, and the most bearish reporting a price target of just DKK403.0.
• In order for you to agree with the analysts, you'd need to believe that by 2029, revenues will be DKK1.5 billion, earnings will come to DKK734.8 million, and it would be trading on a PE ratio of 12.0x, assuming you use a discount rate of 6.1%.
• Given the current share price of DKK337.8, the analyst price target of DKK451.5 is 25.2% higher. Despite analysts expecting the underlying business to decline, they seem to believe it's more valuable than what the market thinks.
• We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.